Background: Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease with limited treatment options. Schisandrin B (Sch B), a bioactive lignan from Schisandra chinensis, has shown anti-inflammatory effects, but its regulatory mechanisms on autophagic flux and non-classical pyroptosis in UC remain unclear.Purpose: To investigate whether Sch B ameliorates colonic inflammation in UC rats by regulating P62-mediated autophagic flux and the P65/caspase4 signaling axis.Study design:In vivo animal study.Methods: A UC model was established in male SD rats using 2,4,6-trinitrobenzenesulfonic acid (TNBS). Rats were randomly divided into six groups(n=10 each): blank control, model, mesalazine (100 mg/kg), and Sch B low(10 mg/kg), medium(20 mg/kg), and high dose(50 mg/kg). Treatments were administered orally for 14 days. Disease activity index (DAI), colonic mucosal injury index(CMDI), and histopathological changes(HE staining) were assessed. Protein expression and localization of P62 and caspase4 were detected by immunohistochemistry (IHC). Western blotting was used to measure P62, phosphorylated P65(P-P65), total P65, and caspase4. Serum levels of IL-18, IL-17A, and IL-10 were measured by ELISA.Results: Compared with the blank group, the model group showed significantly increased DAI and CMDI scores, severe colonic mucosal damage, elevated P62 expression(P<0.01), increased P-P65/P65 ratio, upregulated caspase4 expression, higher serum IL-18 and IL-17A(P<0.01), and lower IL-10(P<0.01). Compared with the model group, Sch B(20 and 50 mg/kg) significantly ameliorated these changes in a dose-dependent manner(P<0.05 or P<0.01), with the high-dose group showing the most pronounced effects.Conclusion: Sch B effectively alleviates TNBS-induced colonic inflammation in UC rats by restoring P62-mediated autophagic flux, inhibiting P65 phosphorylation, downregulating caspase4-mediated non-classical pyroptosis, and rebalancing serum IL-18, IL-17A, and IL-10 levels.